Pro-apoptotic activity of α-bisabolol in preclinical models of primary human acute leukemia cells

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Cavalieri, Elisabetta ^a   Rigo, Antonella ^b   Bonifacio, Massimiliano ^b   de Prati, Alessandra C ^a   Guardalben, Emanuele ^b   Bergamini, Christian ^c   Fato, Romana ^c   Pizzolo, Giovanni ^b   Suzuki, Hisanori ^a   Vinante, Fabrizio ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BISABOLOL; CD33 ANTIGEN; CD34 ANTIGEN; CYTARABINE; DASATINIB; HYDROXYUREA; IDARUBICIN; IMATINIB; NILOTINIB; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; BCR ABL PROTEIN; PIPERAZINE DERIVATIVE; PROTEIN BID; PYRIMIDINE DERIVATIVE; SESQUITERPENE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD TRANSFUSION; CANCER RESISTANCE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; BIOLOGICAL MODEL; BLAST CELL CRISIS; BLOOD CELL; CELL RESPIRATION; CHEMISTRY; CLUSTER ANALYSIS; CULTURE MEDIUM; DRUG EFFECT; DRUG SCREENING; GENETICS; LEUKEMIA; METABOLISM; MIDDLE AGED; MITOCHONDRION; MUTATION; PATHOLOGY; SOLUBILITY; TIME; TUMOR CELL CULTURE;

ADOLESCENT; ADULT; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BLAST CRISIS; BLOOD CELLS; CELL RESPIRATION; CLUSTER ANALYSIS; CULTURE MEDIA; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MIDDLE AGED; MITOCHONDRIA; MODELS, BIOLOGICAL; MUTATION; PIPERAZINES; PYRIMIDINES; SESQUITERPENES; SOLUBILITY; TIME FACTORS; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 79954590785     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-45     Document Type: Article

References (30)

1. Cavalieri E, Mariotto S, Fabrizi C, De Prati AC, Gottardo R, Leone S, Berra LV, Lauro GM, Ciampa AR, Suzuki H. α-bisabolol, a non-toxic natural compound, strongly induces apoptosis in glioma cells. Biochem Biophys Res Commun 2004, 315:589-594. 10.1016/j.bbrc.2004.01.088, 14975741.
2. Costarelli L, Malavolta M, Giacconi R, Cipriano C, Gasparini N, Tesei S, Pierpaoli S, Orlando F, Suzuki H, Perbellini L, Piacenza F, Emanuelli M, Mocchegiani E. In vivo effect of alpha-bisabolol, a nontoxic sesquiterpene alcohol, on the induction of spontaneous mammary tumors in HER-2/neu transgenic mice. Oncol Res 2010, 18:409-418. 10.3727/096504010X12671222663557, 20524399.
3. Darra E, Abdel-Azeim S, Manara A, Shoji K, Marechal JD, Mariotto S, Cavalieri E, Perbellini L, Pizza C, Perahia D, Crimi M, Suzuki H. Insight into the apoptosis-inducing action of α-bisabolol towards malignant tumor cells: Involvement of lipid rafts and Bid. Arch Biochem Biophys 2008, 476:113-123. 10.1016/j.abb.2008.02.004, 18291090.
4. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood 2005, 106:1154-1163. 10.1182/blood-2005-01-0178, 15870183.
5. Appelbaum FR, Rosenblum D, Arceci RJ, Carroll WL, Breitfeld PP, Forman SJ, Larson RA, Lee SJ, Murphy SB, O'Brien S, Radich J, Scher NS, Smith FO, Stone RM, Tallman MS. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood 2007, 109:1810-1816. 10.1182/blood-2006-08-041152, 17095617.
6. Lancet JE, Giralt S. Therapy for older AML patients: the role of novel agents and allogeneic stem cell transplant. J Natl Compr Canc Netw 2008, 6:1017-1025.
7. Kohrt HE, Coutre SE. Optimizing therapy for acute myeloid leukemia. J Natl Compr Canc Netw 2008, 6:1003-1016.
8. Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006, 108:2332-2338. 10.1182/blood-2006-02-004580, 1895563, 16772610.
9. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Bradford S, Agarwal P, Gollerkeri A, Baccarani M. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or intolerant chronic myeloid leukemia in blast crisis. Blood 2007, 109:3207-3213. 10.1182/blood-2006-09-046888, 17185463.
10. Todeschini G, Tecchio C, Meneghini V, Pizzolo G, Veneri D, Zanotti R, Ricetti MM, Solero P, Aprili F, Perona G. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia 1998, 12:144-149. 10.1038/sj.leu.2400912, 9519775.
11. Vitale A, Guarini A, Ariola C, Mancini M, Mecucci C, Cuneo A, Pane F, Saglio G, Cimino G, Tafuri A, Meloni G, Fabbiano F, Recchia A, Kropp MG, Krampera M, Cascavilla N, Ferrara F, Romano A, Mazza P, Fozza C, Paoloni F, Vignetti M, Foà R. Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood 2006, 107:473-479. 10.1182/blood-2005-04-1754, 16179376.
12. Ratei R, Basso G, Dworzak M, Gaipa G, Veltroni M, Rhein P, Biondi A, Schrappe M, Ludwig WD, Karawajew L, . for the AIEOP-BFM-FCM-MRD-Study Group Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction. Leukemia 2009, 23:528-534. 10.1038/leu.2008.324, 19020543, for the AIEOP-BFM-FCM-MRD-Study Group.
13. Vinante F, Rigo A, Papini E, Cassatella MA, Pizzolo G. Heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor expression by acute myeloid leukemia cells. Blood 1999, 93:1715-1723.
14. Vinante F, Marchi M, Rigo A, Scapini P, Pizzolo G, Cassatella MA. Granulocyte-macrophage colony-stimulating factor induces expression of heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor and sensitivity to diphtheria toxin in human neutrophils. Blood 1999, 94:3169-3177.
15. Gratama JW, Keeney M, Sutherland DR. Enumeration of CD34+ hematopoietic stem and progenitor cells. Current Protocols in Cytometry 1999, New York: John Wiley & Sons, Robinson JP, Darzynkiewicz Z, Dean PN, Dressler LG, Rabinovitch PS, Stewart CC, Tanke HJ, Wheeless LL, 6.4.1-22.
16. Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
17. Chretien D, Bénit P, Chol M, Lebon S, Rötig A, Munnich A, Rustin P. Assay of mitochondrial respiratory chain complex I in human lymphocytes and cultured skin fibroblasts. Biochem Biophys Res Commun 2003, 301:222-224. 10.1016/S0006-291X(02)03016-4, 12535666.
18. Nougayrède JP, Donnenberg MS. Enteropathogenic Escherichia coli EspF is targeted to mitochondria and is required to initiate the mitochondrial death pathway. Cell Microbiol 2004, 611:1097-1111.
19. Troiano L, Ferraresi R, Lugli E, Nemes E, Roat E, Nasi M, Pinti M, Cossarizza A. Multiparametric analysis of cells with different mitochondrial membrane potential during apoptosis by polychromatic flow cytometry. Nat Protoc 2007, 2:2719-2727. 10.1038/nprot.2007.405, 18007607.
20. Zinkel S, Gross A, Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death and Differentiation 2006, 13:1351-1359. 10.1038/sj.cdd.4401987, 16763616.
21. Cavalieri E, Bergamini C, Mariotto S, Leoni S, Perbellilni L, Darra E, Suzuki H, Fato R, Lenaz G. Involvement of mitochondrial permeability transition pore opening in alpha-bisabolol induced apoptosis. FEBS J 2009, 276:3990-4000. 10.1111/j.1742-4658.2009.07108.x, 19570051.
22. Galluzzi L, Zamzami N, de La Motte Rouge T, Lemaire C, Brenner C, Kroemer G. Methods for the assessment of mitochondrial membrane permeabilization in apoptosis. Apoptosis 2007, 12:803-813. 10.1007/s10495-007-0720-1, 17294081.
23. Métivier D, Dallaporta B, Zamzami N, Larochette N, Susin SA, Marzo I, Kroemer G. Cytofluorometric detection of mitochondrial alterations in early CD95/Fas/APO-1-triggered apoptosis of Jurkat T lymphoma cells. Comparison of seven mitochondrion-specific fluorochromes. Immunol Lett 1998, 61:157-163. 10.1016/S0165-2478(98)00013-3, 9657269.
24. Bhatia SP, McGinty D, Letizia CS, Api AM. Fragrance Material Review on α-bisabolol. Food Chem Toxicol 2008, 46(Suppl 11):S72-S76.
25. Kamatou GPP, Viljoen AM. A review of the application and pharmacological properties of α-bisabolol and α-bisabolol-rich oils. J Am Oil Chem Soc 2009, 28:1-7.
26. Stanulla M, Schrappe M. Treatment of childhood acute lymphoblastic leukemia. Semin Hematol 2009, 46:52-63. 10.1053/j.seminhematol.2008.09.007, 19100368.
27. Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, Keating MJ, Arkinghaus RB, Huang P. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia 2008, 22:1191-1199. 10.1038/leu.2008.74, 2585768, 18385754.
28. Druker BJ. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 2006, 354:2594-2596. 10.1056/NEJMe068073, 16775240.
29. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL. Dasatinib in imatinib-resistant Philadelphia chromosome positive leukemias. N Engl J Med 2006, 354:2531-2541. 10.1056/NEJMoa055229, 16775234.
30. Lugli E, Troiano L, Ferraresi R, Roat E, Prada N, Nasi M, Pinti M, Cooper EL, Cossarizza A. Characterization of cells with different mitochondrial membrane potential during apoptosis. Cytometry 2005, 68:28-35.